Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

26.7%

4 terminated out of 15 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed with results

Key Signals

8 with results71% success

Data Visualizations

Phase Distribution

15Total
P 1 (15)

Trial Status

Completed10
Terminated4
Active Not Recruiting1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT06970301Phase 1Active Not RecruitingPrimary

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

NCT06679413Phase 1CompletedPrimary

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

NCT05845645Phase 1CompletedPrimary

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT04867642Phase 1CompletedPrimary

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

NCT06312566Phase 1CompletedPrimary

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

NCT04255862Phase 1TerminatedPrimary

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

NCT05292131Phase 1CompletedPrimary

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

NCT04828343Phase 1CompletedPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

NCT05315947Phase 1CompletedPrimary

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

NCT04802746Phase 1CompletedPrimary

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

NCT04444466Phase 1TerminatedPrimary

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

NCT04705350Phase 1CompletedPrimary

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

NCT04136444Phase 1TerminatedPrimary

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

NCT04126343Phase 1TerminatedPrimary

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

NCT04782388Phase 1CompletedPrimary

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

Showing all 15 trials

Research Network

Activity Timeline